|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, September 25, 2017 ) Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Symptoms include depression, irritability and aggression, anxiety and apathy. Risk factors include diabetes, high blood pressure, and depression, smoking and elevated cholesterol.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Mild Cognitive Impairment-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Mild Cognitive Impairment (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 8, 6, 1, 14 and 1 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 2 and 1 molecules, respectively.
Mild Cognitive Impairment (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Request a sample copy at http://www.reportsweb.com/inquiry&RW00011060466/sample
Report Scope
-The pipeline guide provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment (Central Nervous System).
-The pipeline guide reviews pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
-The pipeline guide reviews key companies involved in Mild Cognitive Impairment (Central Nervous System) therapeutics and enlists all their major and minor projects.
-The pipeline guide evaluates Mild Cognitive Impairment (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
-The pipeline guide reviews latest news related to pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System)
For more information about this report at http://www.reportsweb.com/mild-cognitive-impairment-pipeline-review-h2-2017
Reasons to buy
-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
-Find and recognize significant and varied types of therapeutics under development for Mild Cognitive Impairment (Central Nervous System).
-Classify potential new clients or partners in the target demographic.
-Develop tactical initiatives by understanding the focus areas of leading companies.
-Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
-Formulate corrective measures for pipeline projects by understanding Mild Cognitive Impairment (Central Nervous System) pipeline depth and focus of Indication therapeutics.
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
-Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
AgeneBio Inc
Avraham Pharmaceuticals Ltd
CereSpir Inc
ConSynance Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Company
Ensol Biosciences Inc
Genzyme Corp
IntelGenx Corp
Krenitsky Pharmaceuticals Inc
Merck & Co Inc
Nanotherapeutics Inc
Neuron Biopharma SA
Pfizer Inc
Sage Therapeutics Inc
SBI Pharmaceuticals Co Ltd
Suven Life Sciences Ltd
Takeda Pharmaceutical Company Ltd
Therapix Biosciences Ltd
Ask for Discount at http://www.reportsweb.com/inquiry&RW00011060466/discount
List of Tables
Number of Products under Development for Mild Cognitive Impairment, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Mild Cognitive Impairment-Pipeline by AgeneBio Inc, H2 2017
Mild Cognitive Impairment-Pipeline by Avraham Pharmaceuticals Ltd, H2 2017
Mild Cognitive Impairment-Pipeline by CereSpir Inc, H2 2017
Mild Cognitive Impairment-Pipeline by ConSynance Therapeutics Inc, H2 2017
Mild Cognitive Impairment-Pipeline by Eisai Co Ltd, H2 2017
Mild Cognitive Impairment-Pipeline by Eli Lilly and Company, H2 2017
Mild Cognitive Impairment-Pipeline by Ensol Biosciences Inc, H2 2017
Mild Cognitive Impairment-Pipeline by Genzyme Corp, H2 2017
Mild Cognitive Impairment-Pipeline by IntelGenx Corp, H2 2017
Mild Cognitive Impairment-Pipeline by Krenitsky Pharmaceuticals Inc, H2 2017
Mild Cognitive Impairment-Pipeline by Merck & Co Inc, H2 2017
Mild Cognitive Impairment-Pipeline by Nanotherapeutics Inc, H2 2017
Mild Cognitive Impairment-Pipeline by Neuron Biopharma SA, H2 2017
Mild Cognitive Impairment-Pipeline by Pfizer Inc, H2 2017
Mild Cognitive Impairment-Pipeline by Sage Therapeutics Inc, H2 2017
Mild Cognitive Impairment-Pipeline by SBI Pharmaceuticals Co Ltd, H2 2017
Mild Cognitive Impairment-Pipeline by Suven Life Sciences Ltd, H2 2017
Mild Cognitive Impairment-Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW00011060466/buy/2000
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
